[A systematic review and expert's analysis of risk factors of infections in adults due to carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii in Spain]
- PMID: 33913312
- PMCID: PMC8329577
- DOI: 10.37201/req/034.2021
[A systematic review and expert's analysis of risk factors of infections in adults due to carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii in Spain]
Abstract
Objective: The aim of the study is to identify risk factors associated to infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) and carbapenem-resistant Acinetobacter baumannii (CRAB) in adult patients through a systematic literature review, classify them according to their importance and provide recommendations by experts in the Spanish context.
Methods: We developed a systematic literature review to identify risk factors associated to CRPA or CRAB infections and they were evaluated and discussed by a multidisciplinary panel of experts.
Results: There were included 29 studies for P. aeruginosa and 23 for A. baumannii out of 593 identified through systematic literature review. We identified 38 risk factors for P. aeruginosa and 36 for A. baumannii. After risk factor evaluation by the panel of experts, results for CRPA were: 11 important, 10 slightly important and 15 unimportant risk factors; and for CRAB were: 9 important, 5 slightly important and 19 unimportant risk factors. For both pathogens, previous use of antibiotics and hospitalization were important risk factors.
Conclusions: We could identify the main risk factors associated to CRPA and CRAB through literature review. There is a need for developing additional studies with higher levels of evidence to identify sooner and better infected patients through associated risk factors.
Objetivo: El objetivo del estudio es identificar los factores de riesgo asociados a infecciones por Pseudomonas aeruginosa resistente a antibióticos carbapenémicos (PARC) y Acinetobacter baumannii resistente a antibióticos carbapenémicos (ABRC) en pacientes adultos a través de una revisión sistemática de la literatura, clasificarlos según su nivel de importancia y exponer las recomendaciones en el entorno español de un panel de expertos.
Material y métodos: Se llevó a cabo una revisión sistemática de la literatura para identificar los factores de riesgo asociados a PARC o ABRC y posteriormente evaluar cada factor de riesgo por un panel de expertos basándose en la evidencia disponible y su experiencia en la práctica clínica.
Resultados: Se identificaron 593 artículos incluyéndose 29 para PARC y 23 para ABRC. Se identificaron 38 factores de riesgo asociados a PARC y 36 factores de riesgo asociados a ABRC. Tras su evaluación, para PARC, se clasificaron en: 11 importantes, 10 moderadamente importantes y 15 poco importantes; y para ABRC, 9 importantes, 5 moderadamente importantes y 19 poco importantes. Para ambos patógenos, los factores de riesgo importantes estuvieron relacionados con el uso previo de antibióticos y la hospitalización.
Conclusión: Se han identificado los principales factores de riesgo asociados a PARC y ABRC mediante una revisión de la evidencia disponible. Sin embargo, son necesarios estudios adicionales prospectivos que permitan identificar los pacientes con infecciones por dichos patógenos.
Keywords: Acinetobacter baumannii; Pseudomonas aeruginosa; carbapenem resistance; risk factor.
©The Author 2021. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
Conflict of interest statement
RC ha participado en programas de educación organizado por MSD, Pfizer y Shionogi y trabajado en proyectos de investigación financiados por MSD, Pfizer and Shionogi. AS ha participado como ponente y reuniones de asesoramiento para Pfizer, MSD, Angelini, Gilead Sciences y Shionogi. JGM ha participado como ponente actividades educacionales para MSD, Pfizer, Gilead Sciences y Shionogi. MS ha colaborado en proyectos formativos o de investigación y formado parte de simposios, reuniones o asesorías organizadas o financiadas por Gilead, MSD, Janssen, Pfizer y Shionogi. RF ha participado como ponente o como asesor para MSD, Pfizer, Shionogi, Gilead, Grifols y Menarini. JLP ha participado en programas de educación y reuniones de asesoramiento organizadas por Novartis, MSD, Pfizer y Gilead y trabajado en proyectos de investigación financiados por Novartis.
Figures



Similar articles
-
Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study.BMC Infect Dis. 2022 May 24;22(1):491. doi: 10.1186/s12879-022-07436-w. BMC Infect Dis. 2022. PMID: 35610601 Free PMC article.
-
blaVIM- and blaOXA-mediated carbapenem resistance among Acinetobacter baumannii and Pseudomonas aeruginosa isolates from the Mulago hospital intensive care unit in Kampala, Uganda.BMC Infect Dis. 2019 Oct 16;19(1):853. doi: 10.1186/s12879-019-4510-5. BMC Infect Dis. 2019. PMID: 31619192 Free PMC article.
-
Prevalence of carbapenem resistance in Acinetobacter baumannii and Pseudomonas aeruginosa in sub-Saharan Africa: A systematic review and meta-analysis.PLoS One. 2023 Nov 28;18(11):e0287762. doi: 10.1371/journal.pone.0287762. eCollection 2023. PLoS One. 2023. PMID: 38015906 Free PMC article.
-
Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme-drug resistance, and pan-drug resistance in Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review and meta-analysis.Int J Infect Dis. 2018 Nov;76:48-57. doi: 10.1016/j.ijid.2018.05.017. Epub 2018 Jun 2. Int J Infect Dis. 2018. PMID: 29870795
-
Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.Microb Drug Resist. 2017 Oct;23(7):852-863. doi: 10.1089/mdr.2016.0219. Epub 2017 Feb 24. Microb Drug Resist. 2017. PMID: 28437232
Cited by
-
A systematic literature review and expert consensus on risk factors associated to infection progression in adult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteria.Rev Esp Quimioter. 2022 Oct;35(5):455-467. doi: 10.37201/req/062.2022. Epub 2022 Jul 21. Rev Esp Quimioter. 2022. PMID: 35859521 Free PMC article.
References
-
- Sociedad Española de Medicina Preventiva Salud Pública e Higiene ESTUDIO EPINE-EPPS no 30: 2019 Informe España. Estud EPiNE. 2019, 33–36.
-
- Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. . Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019; 19:56–66. doi:10.1016/S1473-3099(18)30605-4. - DOI - PMC - PubMed
-
- WHO Press . Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2013; 1–7. doi:10.1590/S0100-15742013000100018. - DOI
-
- Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect. 2019; 8:1747–1759, doi:10.1080/22221751.2019.1698273. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources